Skip to content

Transcutaneous Auricular Vagus Nerve Stimulation and Spirometry: Sham-Controlled Randomized Trial

Acute Effects Transcutaneous Auricular Vagus Nerve Stimulation on Spirometric Parameters in Healthy Individuals: A Sham-Controlled Randomized Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07482930
Acronym
taVNS-SPIRO
Enrollment
50
Registered
2026-03-19
Start date
2026-03-17
Completion date
2026-04-25
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autonomic Nervous System (ANS) Functioning and Mood State, Blood Pressure Monitoring, Respiratory Function Tests, Spirometry, Vagus Nerve Stimulations

Keywords

transcutaneous auricular vagus nerve stimulation, spirometry, autonomic nervous system, sham stimulation, pulmonary function test, blood pressure

Brief summary

This study will examine the short-term effects of transcutaneous auricular vagus nerve stimulation (a non-invasive electrical stimulation delivered through the outer ear) on lung function measured by spirometry in healthy adults. The vagus nerve is involved in many automatic body functions, and ear-based stimulation has been used in research to explore its possible effects on different physiological systems. However, it is not clear whether a brief stimulation session can acutely influence breathing test results in people without respiratory disease. Healthy volunteers aged 18-40 will take part in one laboratory visit. Participants will be randomly assigned to one of two groups: (1) active bilateral stimulation applied to specific ear regions that are known to be innervated by the vagus nerve, or (2) sham stimulation using the same device setup but designed to minimize vagal activation. The stimulation session will last approximately 10 minutes. Before and after the stimulation, participants will perform standard spirometry (breathing) tests. Primary spirometric outcomes will include common measures of lung function such as forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF). Heart rate, heart rate variability, and blood pressure may also be recorded to monitor physiological responses and safety during the visit. Participation is voluntary and participants may withdraw at any time. The procedure is considered minimal risk. Possible side effects are usually mild and temporary, such as tingling, warmth, or mild discomfort at the ear. Rarely, participants may feel lightheaded; if this occurs, the procedure will be stopped and the participant will be monitored until symptoms resolve. There is no guaranteed direct benefit to participants. The results may help clarify whether short-term ear-based vagus nerve stimulation can influence spirometric parameters and may inform future studies on autonomic and respiratory interactions.

Detailed description

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive neuromodulation approach delivered through the external ear. The auricular branch of the vagus nerve provides an accessible peripheral route that may influence autonomic regulation and, through autonomic-respiratory interactions, potentially affect respiratory function. Although taVNS has been investigated across several physiological domains, evidence regarding its acute effects on spirometric outcomes in healthy individuals remains limited. This study is designed to evaluate whether a single, brief session of bilateral taVNS produces measurable short-term changes in standard spirometric parameters compared with a sham procedure. This is a sham-controlled, randomized, single-blind, parallel-group trial conducted in healthy volunteers. Participants are allocated to either active bilateral taVNS or sham stimulation using a predefined randomization procedure and concealed assignment. To minimize expectancy effects, participants are blinded to group allocation, and active and sham procedures use the same device appearance and session structure. Active stimulation is delivered via electrodes positioned on auricular regions targeted for vagal innervation, whereas sham stimulation uses an alternative placement intended to minimize vagal activation while maintaining a similar sensory experience. Stimulation parameters are standardized across participants, with intensity individually titrated to a clearly perceptible but non-painful level. The primary outcomes are acute pre-to-post changes in spirometric measures obtained using standardized spirometry procedures. Key spirometric endpoints include forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and peak expiratory flow (PEF). Secondary physiological measures may include heart rate, heart rate variability indices, and blood pressure to characterize autonomic and hemodynamic responses and to support safety monitoring during the session. All measurements are collected within the same visit, with spirometry performed immediately before and after the stimulation procedure following consistent instructions and quality criteria. Data analysis will focus on between-group comparisons of change scores (post minus pre) for spirometric outcomes. Depending on distributional assumptions, analyses will use appropriate parametric or non-parametric methods; when relevant, models adjusting for baseline values will be applied (e.g., ANCOVA with baseline spirometry as a covariate). Effect sizes and confidence intervals will be reported to support interpretability. Safety will be monitored throughout the visit; stimulation will be discontinued if a participant experiences significant discomfort or requests stopping. The study involves minimal risk. Expected adverse effects are transient and mild (e.g., localized tingling or mild discomfort at the ear). Rarely, lightheadedness may occur; participants will be monitored and the procedure stopped if necessary. Data will be stored in a coded/de-identified format and reported at the group level.

Interventions

DEVICETranscutaneous auricular vagus nerve stimulation

Transcutaneous auricular vagus nerve stimulation is delivered bilaterally using an external stimulator with electrodes placed on auricular regions targeted for vagal innervation (e.g., cymba conchae). Stimulation is applied for approximately 10 minutes. Parameters are standardized (e.g., 25 Hz; pulse width 200-300 microseconds), and current intensity is individually adjusted to a clearly perceptible but non-painful level. The procedure is performed in a single visit with pre- and post-intervention spirometry and physiological monitoring as specified in the protocol.

DEVICESham transcutaneous auricular stimulation

Sham stimulation uses the same device, setup, and session duration to mimic the active procedure. Electrodes are placed on an ear location intended to minimize vagal activation (e.g., ear lobule), and stimulation is delivered at a minimal/low level to provide a similar sensation without therapeutic vagal stimulation. Pre- and post-session spirometry and other measurements are collected identically to the active arm.

Sponsors

SEFA HAKTAN HATIK
Lead SponsorOTHER
Sinop University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participants and outcome assessors are blinded to group assignment. Active and sham procedures use the same device appearance and session structure; sham stimulation is delivered using an alternative ear placement intended to minimize vagal activation while maintaining a similar sensory experience. Group allocation is coded, and spirometry and other outcome data are recorded/analyzed using these codes until primary analyses are completed.

Intervention model description

Parallel-group, sham-controlled, randomized, single-blind trial. Healthy volunteers are randomly assigned to either active bilateral transcutaneous auricular vagus nerve stimulation or a sham stimulation condition. Spirometric outcomes (e.g., FVC, FEV1, PEF) are measured pre- and post-intervention within a single visit, and between-group differences in change scores are compared.

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 18-40 years. * Healthy volunteers. * Able to perform spirometry and follow study instructions. * Provided written informed consent.

Exclusion criteria

* Any cardiovascular disease, cardiac arrhythmia, hypertension, or related condition. * Any neurological disorder (e.g., diabetes mellitus, peripheral neuropathy, epilepsy). * Any diagnosed psychiatric disorder. * Any respiratory disease (e.g., asthma, chronic obstructive pulmonary disease). * Pregnancy or suspected pregnancy. * Ear conditions that prevent stimulation (infection, open wound, pain/tenderness) or presence of a piercing at/near the stimulation site. * Vigorous exercise within 24 hours prior to measurement. * Caffeine intake, smoking, or alcohol consumption within 4-6 hours prior to measurement. * Marked intolerance or hypersensitivity to the device or the procedure. * Inability to follow instructions during measurements or refusal to complete the session.

Design outcomes

Primary

MeasureTime frameDescription
Change in forced expiratory volume in 1 second (FEV1)Single visit: assessed pre-intervention and immediately post-intervention (within the same session).Forced expiratory volume in 1 second (FEV1), reported in liters (L), will be measured immediately before and immediately after the intervention. The outcome will be defined as the pre-to-post change (post minus pre), and between-group differences in change between active stimulation and sham control will be evaluated.\[FVC\], and peak expiratory flow \[PEF\]) will be measured immediately before and immediately after the intervention. The primary endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.
Change in forced vital capacity (FVC)Single visit: assessed pre-intervention and immediately post-intervention (within the same session).Forced vital capacity (FVC), reported in liters (L), will be measured immediately before and immediately after the intervention. The outcome will be defined as the pre-to-post change (post minus pre), and between-group differences in change between active stimulation and sham control will be evaluated.
Change in peak expiratory flow (PEF)Single visit: assessed pre-intervention and immediately post-intervention (within the same session).Peak expiratory flow (PEF), reported in liters per minute (L/min), will be measured immediately before and immediately after the intervention. The outcome will be defined as the pre-to-post change (post minus pre), and between-group differences in change between active stimulation and sham control will be evaluated.

Secondary

MeasureTime frameDescription
Change in RMSSD from chest recordingsSingle visit: assessed pre-intervention and immediately post-intervention (within the same session).Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. The root mean square of successive differences (RMSSD), reported in milliseconds (ms), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.
Change in SDNN from chest recordingsSingle visit: assessed pre-intervention and immediately post-intervention (within the same session).Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. The standard deviation of normal-to-normal intervals (SDNN), reported in milliseconds (ms), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.
Change in LF power from chest recordingsSingle visit: assessed pre-intervention and immediately post-intervention (within the same session).Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. Low-frequency (LF) power, reported in milliseconds squared (ms²), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.
Change in HF power from chest recordingsSingle visit: assessed pre-intervention and immediately post-intervention (within the same session).Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. High-frequency (HF) power, reported in milliseconds squared (ms²), will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.
Change in LF/HF ratio from chest recordingsSingle visit: assessed pre-intervention and immediately post-intervention (within the same session).Heart rate variability will be recorded from chest-based beat-to-beat intervals before and after the intervention in a standardized resting condition. The low-frequency/high-frequency (LF/HF) ratio, reported as a unitless measure, will be derived from these recordings. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active bilateral stimulation and sham control.
Change in systolic blood pressure (SBP)Single visit: assessed pre-intervention and immediately post-intervention (within the same session).Systolic blood pressure (SBP), reported in millimeters of mercury (mmHg), will be measured before and after the intervention under standardized conditions. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.
Change in diastolic blood pressure (DBP)Single visit: assessed pre-intervention and immediately post-intervention (within the same session).Diastolic blood pressure (DBP), reported in millimeters of mercury (mmHg), will be measured before and after the intervention under standardized conditions. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.
Change in heart rateSingle visit: assessed pre-intervention and immediately post-intervention (within the same session).Heart rate, reported in beats per minute (bpm), will be measured before and after the intervention under standardized conditions. The endpoint is the pre-to-post change (post minus pre) and the between-group difference in change between active stimulation and sham control.

Countries

Turkey (Türkiye)

Contacts

CONTACTSEFA HAKTAN HATIK, MSc, PhD
haktanhtk@gmail.com+90 368 271 55 28

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026